Wyeth Says NSAID Risk Label May Confuse Consumers
This article was originally published in The Tan Sheet
Executive Summary
Available evidence may not support a new FDA-requested NSAID cardiovascular risk warning for ibuprofen in an over-the-counter use context, according to Wyeth
You may also be interested in...
FDA Proposes Liver, GI Risk Warnings For OTC Pain Relievers
FDA proposes adding warnings on labeling for OTC pain relievers to advise consumers of "potential health risks" associated with acetaminophen and NSAIDs such as aspirin, ibuprofen and naproxen
FDA Proposes Liver, GI Risk Warnings For OTC Pain Relievers
FDA proposes adding warnings on labeling for OTC pain relievers to advise consumers of "potential health risks" associated with acetaminophen and NSAIDs such as aspirin, ibuprofen and naproxen
FDA Proposes Liver, GI Risk Warnings For OTC Pain Relievers
FDA proposes adding warnings on labeling for OTC pain relievers to advise consumers of "potential health risks" associated with acetaminophen and NSAIDs such as aspirin, ibuprofen and naproxen